nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Zonisamide—epilepsy syndrome	0.433	1	CiPCiCtD
Vemurafenib—ABCG2—epilepsy syndrome	0.0922	0.495	CbGaD
Vemurafenib—CYP2D6—epilepsy syndrome	0.0538	0.289	CbGaD
Vemurafenib—ALB—epilepsy syndrome	0.0402	0.216	CbGaD
Vemurafenib—ABCC1—Phenobarbital—epilepsy syndrome	0.0213	0.0935	CbGbCtD
Vemurafenib—ALB—Oxcarbazepine—epilepsy syndrome	0.0196	0.0859	CbGbCtD
Vemurafenib—ALB—Fosphenytoin—epilepsy syndrome	0.0171	0.0751	CbGbCtD
Vemurafenib—ALB—Clonazepam—epilepsy syndrome	0.0155	0.0679	CbGbCtD
Vemurafenib—ALB—Rufinamide—epilepsy syndrome	0.0126	0.0554	CbGbCtD
Vemurafenib—ALB—Phenytoin—epilepsy syndrome	0.011	0.0484	CbGbCtD
Vemurafenib—ALB—Propofol—epilepsy syndrome	0.0103	0.0451	CbGbCtD
Vemurafenib—ALB—Diazepam—epilepsy syndrome	0.00932	0.0409	CbGbCtD
Vemurafenib—CYP1A2—Carbamazepine—epilepsy syndrome	0.00736	0.0323	CbGbCtD
Vemurafenib—CYP1A2—Primidone—epilepsy syndrome	0.00687	0.0301	CbGbCtD
Vemurafenib—CYP1A2—Propofol—epilepsy syndrome	0.00615	0.027	CbGbCtD
Vemurafenib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00614	0.0269	CbGbCtD
Vemurafenib—CYP1A2—Phenobarbital—epilepsy syndrome	0.00588	0.0258	CbGbCtD
Vemurafenib—CYP3A4—Felbamate—epilepsy syndrome	0.00571	0.025	CbGbCtD
Vemurafenib—CYP3A4—Trimethadione—epilepsy syndrome	0.00571	0.025	CbGbCtD
Vemurafenib—CYP1A2—Diazepam—epilepsy syndrome	0.00557	0.0245	CbGbCtD
Vemurafenib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00536	0.0235	CbGbCtD
Vemurafenib—CYP2D6—Propofol—epilepsy syndrome	0.00507	0.0222	CbGbCtD
Vemurafenib—CYP3A4—Clonazepam—epilepsy syndrome	0.00485	0.0213	CbGbCtD
Vemurafenib—CYP3A4—Clobazam—epilepsy syndrome	0.00465	0.0204	CbGbCtD
Vemurafenib—CYP1A2—Valproic Acid—epilepsy syndrome	0.00439	0.0193	CbGbCtD
Vemurafenib—CYP3A4—Rufinamide—epilepsy syndrome	0.00395	0.0174	CbGbCtD
Vemurafenib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00385	0.0169	CbGbCtD
Vemurafenib—CYP3A4—Primidone—epilepsy syndrome	0.0036	0.0158	CbGbCtD
Vemurafenib—CYP3A4—Phenytoin—epilepsy syndrome	0.00346	0.0152	CbGbCtD
Vemurafenib—CYP3A4—Propofol—epilepsy syndrome	0.00322	0.0141	CbGbCtD
Vemurafenib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00308	0.0135	CbGbCtD
Vemurafenib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00308	0.0135	CbGbCtD
Vemurafenib—CYP3A4—Midazolam—epilepsy syndrome	0.00304	0.0133	CbGbCtD
Vemurafenib—CYP3A4—Diazepam—epilepsy syndrome	0.00292	0.0128	CbGbCtD
Vemurafenib—CYP3A4—Zonisamide—epilepsy syndrome	0.00285	0.0125	CbGbCtD
Vemurafenib—CYP3A4—Valproic Acid—epilepsy syndrome	0.0023	0.0101	CbGbCtD
Vemurafenib—CYP3A4—Topiramate—epilepsy syndrome	0.00208	0.00911	CbGbCtD
Vemurafenib—RAF1—hindbrain—epilepsy syndrome	0.000749	0.1	CbGeAlD
Vemurafenib—Etoricoxib—CYP2C19—epilepsy syndrome	0.00049	0.423	CrCbGaD
Vemurafenib—RAF1—brainstem—epilepsy syndrome	0.000429	0.0573	CbGeAlD
Vemurafenib—RAF1—forebrain—epilepsy syndrome	0.000414	0.0553	CbGeAlD
Vemurafenib—BRAF—midbrain—epilepsy syndrome	0.000411	0.0548	CbGeAlD
Vemurafenib—RAF1—telencephalon—epilepsy syndrome	0.000381	0.0509	CbGeAlD
Vemurafenib—Etoricoxib—CYP2D6—epilepsy syndrome	0.000364	0.314	CrCbGaD
Vemurafenib—BRAF—cerebellum—epilepsy syndrome	0.000318	0.0424	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—epilepsy syndrome	0.000305	0.263	CrCbGaD
Vemurafenib—RAF1—medulla oblongata—epilepsy syndrome	0.000299	0.04	CbGeAlD
Vemurafenib—RAF1—midbrain—epilepsy syndrome	0.000274	0.0365	CbGeAlD
Vemurafenib—RAF1—spinal cord—epilepsy syndrome	0.000267	0.0356	CbGeAlD
Vemurafenib—BRAF—brain—epilepsy syndrome	0.000258	0.0345	CbGeAlD
Vemurafenib—RAF1—head—epilepsy syndrome	0.000237	0.0317	CbGeAlD
Vemurafenib—RAF1—nervous system—epilepsy syndrome	0.000225	0.03	CbGeAlD
Vemurafenib—RAF1—central nervous system—epilepsy syndrome	0.000217	0.0289	CbGeAlD
Vemurafenib—CYP2D6—hindbrain—epilepsy syndrome	0.000212	0.0284	CbGeAlD
Vemurafenib—RAF1—cerebellum—epilepsy syndrome	0.000212	0.0283	CbGeAlD
Vemurafenib—ABCC1—telencephalon—epilepsy syndrome	0.00019	0.0254	CbGeAlD
Vemurafenib—ORM1—spinal cord—epilepsy syndrome	0.000184	0.0246	CbGeAlD
Vemurafenib—RAF1—brain—epilepsy syndrome	0.000172	0.023	CbGeAlD
Vemurafenib—ABCG2—telencephalon—epilepsy syndrome	0.000158	0.021	CbGeAlD
Vemurafenib—ORM1—nervous system—epilepsy syndrome	0.000155	0.0207	CbGeAlD
Vemurafenib—ORM1—central nervous system—epilepsy syndrome	0.00015	0.02	CbGeAlD
Vemurafenib—ABCG2—medulla oblongata—epilepsy syndrome	0.000124	0.0165	CbGeAlD
Vemurafenib—CYP2D6—brainstem—epilepsy syndrome	0.000122	0.0163	CbGeAlD
Vemurafenib—CYP2D6—forebrain—epilepsy syndrome	0.000118	0.0157	CbGeAlD
Vemurafenib—ABCG2—midbrain—epilepsy syndrome	0.000113	0.0151	CbGeAlD
Vemurafenib—ABCG2—spinal cord—epilepsy syndrome	0.00011	0.0147	CbGeAlD
Vemurafenib—CYP2D6—telencephalon—epilepsy syndrome	0.000108	0.0144	CbGeAlD
Vemurafenib—ABCC1—cerebellum—epilepsy syndrome	0.000106	0.0141	CbGeAlD
Vemurafenib—ALB—brain—epilepsy syndrome	0.000104	0.0139	CbGeAlD
Vemurafenib—ABCG2—cerebellum—epilepsy syndrome	8.76e-05	0.0117	CbGeAlD
Vemurafenib—ABCC1—brain—epilepsy syndrome	8.59e-05	0.0115	CbGeAlD
Vemurafenib—ABCG2—brain—epilepsy syndrome	7.11e-05	0.0095	CbGeAlD
Vemurafenib—CYP2D6—head—epilepsy syndrome	6.73e-05	0.00898	CbGeAlD
Vemurafenib—CYP3A4—nervous system—epilepsy syndrome	6.48e-05	0.00866	CbGeAlD
Vemurafenib—CYP2D6—nervous system—epilepsy syndrome	6.38e-05	0.00852	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—epilepsy syndrome	6.24e-05	0.00833	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—epilepsy syndrome	6.14e-05	0.0082	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—epilepsy syndrome	6e-05	0.00802	CbGeAlD
Vemurafenib—Malnutrition—Pregabalin—epilepsy syndrome	5.97e-05	0.000759	CcSEcCtD
Vemurafenib—Erythema multiforme—Gabapentin—epilepsy syndrome	5.94e-05	0.000756	CcSEcCtD
Vemurafenib—Asthenia—Vigabatrin—epilepsy syndrome	5.91e-05	0.000751	CcSEcCtD
Vemurafenib—Decreased appetite—Lamotrigine—epilepsy syndrome	5.89e-05	0.000749	CcSEcCtD
Vemurafenib—Infestation—Topiramate—epilepsy syndrome	5.89e-05	0.000749	CcSEcCtD
Vemurafenib—Infestation NOS—Topiramate—epilepsy syndrome	5.89e-05	0.000749	CcSEcCtD
Vemurafenib—Eye disorder—Gabapentin—epilepsy syndrome	5.88e-05	0.000747	CcSEcCtD
Vemurafenib—Dizziness—Midazolam—epilepsy syndrome	5.86e-05	0.000745	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	5.85e-05	0.000744	CcSEcCtD
Vemurafenib—Body temperature increased—Clonazepam—epilepsy syndrome	5.85e-05	0.000744	CcSEcCtD
Vemurafenib—Fatigue—Lamotrigine—epilepsy syndrome	5.85e-05	0.000743	CcSEcCtD
Vemurafenib—Dysgeusia—Pregabalin—epilepsy syndrome	5.84e-05	0.000743	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Topiramate—epilepsy syndrome	5.84e-05	0.000743	CcSEcCtD
Vemurafenib—Cardiac disorder—Gabapentin—epilepsy syndrome	5.83e-05	0.000742	CcSEcCtD
Vemurafenib—Pruritus—Vigabatrin—epilepsy syndrome	5.82e-05	0.00074	CcSEcCtD
Vemurafenib—Asthenia—Diazepam—epilepsy syndrome	5.81e-05	0.000739	CcSEcCtD
Vemurafenib—Body temperature increased—Phenytoin—epilepsy syndrome	5.81e-05	0.000739	CcSEcCtD
Vemurafenib—Constipation—Lamotrigine—epilepsy syndrome	5.8e-05	0.000737	CcSEcCtD
Vemurafenib—Nausea—Acetazolamide—epilepsy syndrome	5.79e-05	0.000736	CcSEcCtD
Vemurafenib—Dizziness—Levetiracetam—epilepsy syndrome	5.79e-05	0.000735	CcSEcCtD
Vemurafenib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	5.78e-05	0.000735	CcSEcCtD
Vemurafenib—Diarrhoea—Fosphenytoin—epilepsy syndrome	5.78e-05	0.000734	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Topiramate—epilepsy syndrome	5.78e-05	0.000734	CcSEcCtD
Vemurafenib—Back pain—Pregabalin—epilepsy syndrome	5.77e-05	0.000734	CcSEcCtD
Vemurafenib—Cough—Valproic Acid—epilepsy syndrome	5.76e-05	0.000732	CcSEcCtD
Vemurafenib—Vomiting—Propofol—epilepsy syndrome	5.76e-05	0.000732	CcSEcCtD
Vemurafenib—Pruritus—Diazepam—epilepsy syndrome	5.73e-05	0.000729	CcSEcCtD
Vemurafenib—Rash—Propofol—epilepsy syndrome	5.71e-05	0.000726	CcSEcCtD
Vemurafenib—Dermatitis—Propofol—epilepsy syndrome	5.7e-05	0.000725	CcSEcCtD
Vemurafenib—Headache—Propofol—epilepsy syndrome	5.67e-05	0.000721	CcSEcCtD
Vemurafenib—Mediastinal disorder—Gabapentin—epilepsy syndrome	5.67e-05	0.00072	CcSEcCtD
Vemurafenib—Hypersensitivity—Zonisamide—epilepsy syndrome	5.66e-05	0.000719	CcSEcCtD
Vemurafenib—Chills—Gabapentin—epilepsy syndrome	5.64e-05	0.000717	CcSEcCtD
Vemurafenib—Vomiting—Midazolam—epilepsy syndrome	5.63e-05	0.000716	CcSEcCtD
Vemurafenib—Diarrhoea—Vigabatrin—epilepsy syndrome	5.63e-05	0.000716	CcSEcCtD
Vemurafenib—Asthenia—Felbamate—epilepsy syndrome	5.63e-05	0.000715	CcSEcCtD
Vemurafenib—Arthralgia—Valproic Acid—epilepsy syndrome	5.62e-05	0.000714	CcSEcCtD
Vemurafenib—Myalgia—Valproic Acid—epilepsy syndrome	5.62e-05	0.000714	CcSEcCtD
Vemurafenib—Rash—Midazolam—epilepsy syndrome	5.59e-05	0.00071	CcSEcCtD
Vemurafenib—Dizziness—Fosphenytoin—epilepsy syndrome	5.58e-05	0.00071	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	5.58e-05	0.00071	CcSEcCtD
Vemurafenib—Dermatitis—Midazolam—epilepsy syndrome	5.58e-05	0.000709	CcSEcCtD
Vemurafenib—Vomiting—Levetiracetam—epilepsy syndrome	5.56e-05	0.000707	CcSEcCtD
Vemurafenib—Alopecia—Gabapentin—epilepsy syndrome	5.56e-05	0.000706	CcSEcCtD
Vemurafenib—Headache—Midazolam—epilepsy syndrome	5.55e-05	0.000706	CcSEcCtD
Vemurafenib—Pruritus—Felbamate—epilepsy syndrome	5.55e-05	0.000705	CcSEcCtD
Vemurafenib—Body temperature increased—Carbamazepine—epilepsy syndrome	5.55e-05	0.000705	CcSEcCtD
Vemurafenib—Diarrhoea—Diazepam—epilepsy syndrome	5.54e-05	0.000705	CcSEcCtD
Vemurafenib—Rash—Levetiracetam—epilepsy syndrome	5.52e-05	0.000701	CcSEcCtD
Vemurafenib—Dermatitis—Levetiracetam—epilepsy syndrome	5.51e-05	0.000701	CcSEcCtD
Vemurafenib—Asthenia—Zonisamide—epilepsy syndrome	5.51e-05	0.0007	CcSEcCtD
Vemurafenib—Headache—Levetiracetam—epilepsy syndrome	5.48e-05	0.000697	CcSEcCtD
Vemurafenib—Erythema—Gabapentin—epilepsy syndrome	5.47e-05	0.000696	CcSEcCtD
Vemurafenib—Malnutrition—Gabapentin—epilepsy syndrome	5.47e-05	0.000696	CcSEcCtD
Vemurafenib—Hypersensitivity—Clonazepam—epilepsy syndrome	5.45e-05	0.000693	CcSEcCtD
Vemurafenib—Dizziness—Vigabatrin—epilepsy syndrome	5.44e-05	0.000692	CcSEcCtD
Vemurafenib—Pruritus—Zonisamide—epilepsy syndrome	5.43e-05	0.00069	CcSEcCtD
Vemurafenib—Hypersensitivity—Phenytoin—epilepsy syndrome	5.42e-05	0.000688	CcSEcCtD
Vemurafenib—Anaphylactic shock—Valproic Acid—epilepsy syndrome	5.39e-05	0.000685	CcSEcCtD
Vemurafenib—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	5.39e-05	0.000685	CcSEcCtD
Vemurafenib—Nausea—Propofol—epilepsy syndrome	5.38e-05	0.000684	CcSEcCtD
Vemurafenib—Vomiting—Fosphenytoin—epilepsy syndrome	5.37e-05	0.000682	CcSEcCtD
Vemurafenib—Diarrhoea—Felbamate—epilepsy syndrome	5.37e-05	0.000682	CcSEcCtD
Vemurafenib—Body temperature increased—Lamotrigine—epilepsy syndrome	5.36e-05	0.000681	CcSEcCtD
Vemurafenib—Dysgeusia—Gabapentin—epilepsy syndrome	5.36e-05	0.000681	CcSEcCtD
Vemurafenib—Dizziness—Diazepam—epilepsy syndrome	5.36e-05	0.000681	CcSEcCtD
Vemurafenib—Infection—Valproic Acid—epilepsy syndrome	5.35e-05	0.00068	CcSEcCtD
Vemurafenib—Rash—Fosphenytoin—epilepsy syndrome	5.32e-05	0.000677	CcSEcCtD
Vemurafenib—Dermatitis—Fosphenytoin—epilepsy syndrome	5.32e-05	0.000676	CcSEcCtD
Vemurafenib—Asthenia—Clonazepam—epilepsy syndrome	5.31e-05	0.000675	CcSEcCtD
Vemurafenib—Back pain—Gabapentin—epilepsy syndrome	5.29e-05	0.000673	CcSEcCtD
Vemurafenib—Headache—Fosphenytoin—epilepsy syndrome	5.29e-05	0.000672	CcSEcCtD
Vemurafenib—Nervous system disorder—Valproic Acid—epilepsy syndrome	5.28e-05	0.000672	CcSEcCtD
Vemurafenib—Asthenia—Phenytoin—epilepsy syndrome	5.27e-05	0.00067	CcSEcCtD
Vemurafenib—Nausea—Midazolam—epilepsy syndrome	5.26e-05	0.000669	CcSEcCtD
Vemurafenib—Diarrhoea—Zonisamide—epilepsy syndrome	5.25e-05	0.000668	CcSEcCtD
Vemurafenib—Asthenia—Oxcarbazepine—epilepsy syndrome	5.25e-05	0.000667	CcSEcCtD
Vemurafenib—Pruritus—Clonazepam—epilepsy syndrome	5.24e-05	0.000665	CcSEcCtD
Vemurafenib—Vomiting—Vigabatrin—epilepsy syndrome	5.23e-05	0.000665	CcSEcCtD
Vemurafenib—Skin disorder—Valproic Acid—epilepsy syndrome	5.23e-05	0.000665	CcSEcCtD
Vemurafenib—Oedema peripheral—Topiramate—epilepsy syndrome	5.21e-05	0.000662	CcSEcCtD
Vemurafenib—Cough—Pregabalin—epilepsy syndrome	5.21e-05	0.000662	CcSEcCtD
Vemurafenib—Pruritus—Phenytoin—epilepsy syndrome	5.2e-05	0.000661	CcSEcCtD
Vemurafenib—Connective tissue disorder—Topiramate—epilepsy syndrome	5.2e-05	0.000661	CcSEcCtD
Vemurafenib—Nausea—Levetiracetam—epilepsy syndrome	5.2e-05	0.000661	CcSEcCtD
Vemurafenib—Rash—Vigabatrin—epilepsy syndrome	5.19e-05	0.00066	CcSEcCtD
Vemurafenib—Dizziness—Felbamate—epilepsy syndrome	5.19e-05	0.000659	CcSEcCtD
Vemurafenib—Dermatitis—Vigabatrin—epilepsy syndrome	5.19e-05	0.000659	CcSEcCtD
Vemurafenib—Pruritus—Oxcarbazepine—epilepsy syndrome	5.17e-05	0.000657	CcSEcCtD
Vemurafenib—Hypersensitivity—Carbamazepine—epilepsy syndrome	5.17e-05	0.000657	CcSEcCtD
Vemurafenib—Headache—Vigabatrin—epilepsy syndrome	5.16e-05	0.000655	CcSEcCtD
Vemurafenib—Vomiting—Diazepam—epilepsy syndrome	5.15e-05	0.000655	CcSEcCtD
Vemurafenib—Rash—Diazepam—epilepsy syndrome	5.11e-05	0.000649	CcSEcCtD
Vemurafenib—Dermatitis—Diazepam—epilepsy syndrome	5.1e-05	0.000649	CcSEcCtD
Vemurafenib—Myalgia—Pregabalin—epilepsy syndrome	5.08e-05	0.000646	CcSEcCtD
Vemurafenib—Arthralgia—Pregabalin—epilepsy syndrome	5.08e-05	0.000646	CcSEcCtD
Vemurafenib—Dizziness—Zonisamide—epilepsy syndrome	5.08e-05	0.000645	CcSEcCtD
Vemurafenib—Headache—Diazepam—epilepsy syndrome	5.08e-05	0.000645	CcSEcCtD
Vemurafenib—Diarrhoea—Clonazepam—epilepsy syndrome	5.06e-05	0.000644	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	5.05e-05	0.000641	CcSEcCtD
Vemurafenib—Hypotension—Valproic Acid—epilepsy syndrome	5.03e-05	0.00064	CcSEcCtD
Vemurafenib—Asthenia—Carbamazepine—epilepsy syndrome	5.03e-05	0.00064	CcSEcCtD
Vemurafenib—Diarrhoea—Phenytoin—epilepsy syndrome	5.03e-05	0.000639	CcSEcCtD
Vemurafenib—Nausea—Fosphenytoin—epilepsy syndrome	5.02e-05	0.000638	CcSEcCtD
Vemurafenib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	5e-05	0.000636	CcSEcCtD
Vemurafenib—Erythema multiforme—Topiramate—epilepsy syndrome	5e-05	0.000636	CcSEcCtD
Vemurafenib—Hypersensitivity—Lamotrigine—epilepsy syndrome	5e-05	0.000635	CcSEcCtD
Vemurafenib—Vomiting—Felbamate—epilepsy syndrome	4.99e-05	0.000634	CcSEcCtD
Vemurafenib—Pruritus—Carbamazepine—epilepsy syndrome	4.96e-05	0.000631	CcSEcCtD
Vemurafenib—Rash—Felbamate—epilepsy syndrome	4.95e-05	0.000629	CcSEcCtD
Vemurafenib—Eye disorder—Topiramate—epilepsy syndrome	4.94e-05	0.000628	CcSEcCtD
Vemurafenib—Dermatitis—Felbamate—epilepsy syndrome	4.94e-05	0.000628	CcSEcCtD
Vemurafenib—Headache—Felbamate—epilepsy syndrome	4.91e-05	0.000625	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	4.91e-05	0.000624	CcSEcCtD
Vemurafenib—Cardiac disorder—Topiramate—epilepsy syndrome	4.91e-05	0.000624	CcSEcCtD
Vemurafenib—Dizziness—Clonazepam—epilepsy syndrome	4.89e-05	0.000622	CcSEcCtD
Vemurafenib—Nausea—Vigabatrin—epilepsy syndrome	4.89e-05	0.000621	CcSEcCtD
Vemurafenib—Vomiting—Zonisamide—epilepsy syndrome	4.88e-05	0.00062	CcSEcCtD
Vemurafenib—CYP2D6—brain—epilepsy syndrome	4.88e-05	0.00651	CbGeAlD
Vemurafenib—Anaphylactic shock—Pregabalin—epilepsy syndrome	4.87e-05	0.000619	CcSEcCtD
Vemurafenib—Asthenia—Lamotrigine—epilepsy syndrome	4.86e-05	0.000618	CcSEcCtD
Vemurafenib—Dizziness—Phenytoin—epilepsy syndrome	4.86e-05	0.000618	CcSEcCtD
Vemurafenib—Rash—Zonisamide—epilepsy syndrome	4.84e-05	0.000615	CcSEcCtD
Vemurafenib—Infection—Pregabalin—epilepsy syndrome	4.84e-05	0.000615	CcSEcCtD
Vemurafenib—Dermatitis—Zonisamide—epilepsy syndrome	4.84e-05	0.000615	CcSEcCtD
Vemurafenib—Dizziness—Oxcarbazepine—epilepsy syndrome	4.83e-05	0.000615	CcSEcCtD
Vemurafenib—Nausea—Diazepam—epilepsy syndrome	4.81e-05	0.000612	CcSEcCtD
Vemurafenib—Headache—Zonisamide—epilepsy syndrome	4.81e-05	0.000611	CcSEcCtD
Vemurafenib—Diarrhoea—Carbamazepine—epilepsy syndrome	4.8e-05	0.00061	CcSEcCtD
Vemurafenib—Angiopathy—Topiramate—epilepsy syndrome	4.8e-05	0.00061	CcSEcCtD
Vemurafenib—Pruritus—Lamotrigine—epilepsy syndrome	4.8e-05	0.00061	CcSEcCtD
Vemurafenib—Nervous system disorder—Pregabalin—epilepsy syndrome	4.78e-05	0.000607	CcSEcCtD
Vemurafenib—Cough—Gabapentin—epilepsy syndrome	4.78e-05	0.000607	CcSEcCtD
Vemurafenib—Mediastinal disorder—Topiramate—epilepsy syndrome	4.77e-05	0.000606	CcSEcCtD
Vemurafenib—Chills—Topiramate—epilepsy syndrome	4.75e-05	0.000603	CcSEcCtD
Vemurafenib—Skin disorder—Pregabalin—epilepsy syndrome	4.73e-05	0.000601	CcSEcCtD
Vemurafenib—Vomiting—Clonazepam—epilepsy syndrome	4.7e-05	0.000598	CcSEcCtD
Vemurafenib—Decreased appetite—Valproic Acid—epilepsy syndrome	4.68e-05	0.000595	CcSEcCtD
Vemurafenib—Alopecia—Topiramate—epilepsy syndrome	4.67e-05	0.000594	CcSEcCtD
Vemurafenib—Vomiting—Phenytoin—epilepsy syndrome	4.67e-05	0.000594	CcSEcCtD
Vemurafenib—Rash—Clonazepam—epilepsy syndrome	4.67e-05	0.000593	CcSEcCtD
Vemurafenib—Dermatitis—Clonazepam—epilepsy syndrome	4.66e-05	0.000592	CcSEcCtD
Vemurafenib—Myalgia—Gabapentin—epilepsy syndrome	4.66e-05	0.000592	CcSEcCtD
Vemurafenib—Arthralgia—Gabapentin—epilepsy syndrome	4.66e-05	0.000592	CcSEcCtD
Vemurafenib—Nausea—Felbamate—epilepsy syndrome	4.66e-05	0.000592	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	4.65e-05	0.000591	CcSEcCtD
Vemurafenib—Vomiting—Oxcarbazepine—epilepsy syndrome	4.65e-05	0.000591	CcSEcCtD
Vemurafenib—Fatigue—Valproic Acid—epilepsy syndrome	4.65e-05	0.00059	CcSEcCtD
Vemurafenib—Dizziness—Carbamazepine—epilepsy syndrome	4.64e-05	0.00059	CcSEcCtD
Vemurafenib—Diarrhoea—Lamotrigine—epilepsy syndrome	4.64e-05	0.00059	CcSEcCtD
Vemurafenib—Headache—Clonazepam—epilepsy syndrome	4.64e-05	0.000589	CcSEcCtD
Vemurafenib—Rash—Phenytoin—epilepsy syndrome	4.63e-05	0.000589	CcSEcCtD
Vemurafenib—Dermatitis—Phenytoin—epilepsy syndrome	4.63e-05	0.000589	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	4.63e-05	0.000588	CcSEcCtD
Vemurafenib—Rash—Oxcarbazepine—epilepsy syndrome	4.61e-05	0.000586	CcSEcCtD
Vemurafenib—Constipation—Valproic Acid—epilepsy syndrome	4.61e-05	0.000586	CcSEcCtD
Vemurafenib—Dermatitis—Oxcarbazepine—epilepsy syndrome	4.61e-05	0.000585	CcSEcCtD
Vemurafenib—Headache—Phenytoin—epilepsy syndrome	4.6e-05	0.000585	CcSEcCtD
Vemurafenib—Malnutrition—Topiramate—epilepsy syndrome	4.6e-05	0.000585	CcSEcCtD
Vemurafenib—Erythema—Topiramate—epilepsy syndrome	4.6e-05	0.000585	CcSEcCtD
Vemurafenib—Headache—Oxcarbazepine—epilepsy syndrome	4.58e-05	0.000582	CcSEcCtD
Vemurafenib—Nausea—Zonisamide—epilepsy syndrome	4.56e-05	0.00058	CcSEcCtD
Vemurafenib—Hypotension—Pregabalin—epilepsy syndrome	4.55e-05	0.000579	CcSEcCtD
Vemurafenib—Dysgeusia—Topiramate—epilepsy syndrome	4.51e-05	0.000573	CcSEcCtD
Vemurafenib—Dizziness—Lamotrigine—epilepsy syndrome	4.48e-05	0.00057	CcSEcCtD
Vemurafenib—Anaphylactic shock—Gabapentin—epilepsy syndrome	4.47e-05	0.000568	CcSEcCtD
Vemurafenib—Vomiting—Carbamazepine—epilepsy syndrome	4.46e-05	0.000567	CcSEcCtD
Vemurafenib—Back pain—Topiramate—epilepsy syndrome	4.45e-05	0.000566	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	4.44e-05	0.000564	CcSEcCtD
Vemurafenib—Infection—Gabapentin—epilepsy syndrome	4.44e-05	0.000564	CcSEcCtD
Vemurafenib—Rash—Carbamazepine—epilepsy syndrome	4.42e-05	0.000562	CcSEcCtD
Vemurafenib—Dermatitis—Carbamazepine—epilepsy syndrome	4.42e-05	0.000562	CcSEcCtD
Vemurafenib—Nausea—Clonazepam—epilepsy syndrome	4.4e-05	0.000559	CcSEcCtD
Vemurafenib—Headache—Carbamazepine—epilepsy syndrome	4.4e-05	0.000559	CcSEcCtD
Vemurafenib—Nervous system disorder—Gabapentin—epilepsy syndrome	4.38e-05	0.000557	CcSEcCtD
Vemurafenib—Nausea—Phenytoin—epilepsy syndrome	4.37e-05	0.000555	CcSEcCtD
Vemurafenib—Nausea—Oxcarbazepine—epilepsy syndrome	4.34e-05	0.000552	CcSEcCtD
Vemurafenib—Skin disorder—Gabapentin—epilepsy syndrome	4.34e-05	0.000551	CcSEcCtD
Vemurafenib—Vomiting—Lamotrigine—epilepsy syndrome	4.31e-05	0.000548	CcSEcCtD
Vemurafenib—Rash—Lamotrigine—epilepsy syndrome	4.28e-05	0.000543	CcSEcCtD
Vemurafenib—Dermatitis—Lamotrigine—epilepsy syndrome	4.27e-05	0.000543	CcSEcCtD
Vemurafenib—Body temperature increased—Valproic Acid—epilepsy syndrome	4.26e-05	0.000541	CcSEcCtD
Vemurafenib—Headache—Lamotrigine—epilepsy syndrome	4.25e-05	0.00054	CcSEcCtD
Vemurafenib—Decreased appetite—Pregabalin—epilepsy syndrome	4.23e-05	0.000538	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	4.21e-05	0.000535	CcSEcCtD
Vemurafenib—Fatigue—Pregabalin—epilepsy syndrome	4.2e-05	0.000534	CcSEcCtD
Vemurafenib—Hypotension—Gabapentin—epilepsy syndrome	4.17e-05	0.000531	CcSEcCtD
Vemurafenib—Nausea—Carbamazepine—epilepsy syndrome	4.17e-05	0.00053	CcSEcCtD
Vemurafenib—Constipation—Pregabalin—epilepsy syndrome	4.17e-05	0.000529	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	4.07e-05	0.000517	CcSEcCtD
Vemurafenib—Nausea—Lamotrigine—epilepsy syndrome	4.03e-05	0.000512	CcSEcCtD
Vemurafenib—Cough—Topiramate—epilepsy syndrome	4.02e-05	0.000511	CcSEcCtD
Vemurafenib—Hypersensitivity—Valproic Acid—epilepsy syndrome	3.97e-05	0.000505	CcSEcCtD
Vemurafenib—Myalgia—Topiramate—epilepsy syndrome	3.92e-05	0.000498	CcSEcCtD
Vemurafenib—Arthralgia—Topiramate—epilepsy syndrome	3.92e-05	0.000498	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.89e-05	0.000495	CcSEcCtD
Vemurafenib—Decreased appetite—Gabapentin—epilepsy syndrome	3.88e-05	0.000494	CcSEcCtD
Vemurafenib—Asthenia—Valproic Acid—epilepsy syndrome	3.87e-05	0.000491	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.86e-05	0.00049	CcSEcCtD
Vemurafenib—Fatigue—Gabapentin—epilepsy syndrome	3.85e-05	0.000489	CcSEcCtD
Vemurafenib—Body temperature increased—Pregabalin—epilepsy syndrome	3.85e-05	0.000489	CcSEcCtD
Vemurafenib—Constipation—Gabapentin—epilepsy syndrome	3.82e-05	0.000486	CcSEcCtD
Vemurafenib—Pruritus—Valproic Acid—epilepsy syndrome	3.81e-05	0.000485	CcSEcCtD
Vemurafenib—Infection—Topiramate—epilepsy syndrome	3.73e-05	0.000475	CcSEcCtD
Vemurafenib—Diarrhoea—Valproic Acid—epilepsy syndrome	3.69e-05	0.000469	CcSEcCtD
Vemurafenib—Nervous system disorder—Topiramate—epilepsy syndrome	3.69e-05	0.000468	CcSEcCtD
Vemurafenib—Skin disorder—Topiramate—epilepsy syndrome	3.65e-05	0.000464	CcSEcCtD
Vemurafenib—Hypersensitivity—Pregabalin—epilepsy syndrome	3.59e-05	0.000456	CcSEcCtD
Vemurafenib—Dizziness—Valproic Acid—epilepsy syndrome	3.56e-05	0.000453	CcSEcCtD
Vemurafenib—Body temperature increased—Gabapentin—epilepsy syndrome	3.53e-05	0.000449	CcSEcCtD
Vemurafenib—Hypotension—Topiramate—epilepsy syndrome	3.51e-05	0.000446	CcSEcCtD
Vemurafenib—Asthenia—Pregabalin—epilepsy syndrome	3.49e-05	0.000444	CcSEcCtD
Vemurafenib—Pruritus—Pregabalin—epilepsy syndrome	3.45e-05	0.000438	CcSEcCtD
Vemurafenib—Vomiting—Valproic Acid—epilepsy syndrome	3.43e-05	0.000435	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	3.42e-05	0.000435	CcSEcCtD
Vemurafenib—Rash—Valproic Acid—epilepsy syndrome	3.4e-05	0.000432	CcSEcCtD
Vemurafenib—Dermatitis—Valproic Acid—epilepsy syndrome	3.39e-05	0.000431	CcSEcCtD
Vemurafenib—Headache—Valproic Acid—epilepsy syndrome	3.38e-05	0.000429	CcSEcCtD
Vemurafenib—Diarrhoea—Pregabalin—epilepsy syndrome	3.33e-05	0.000424	CcSEcCtD
Vemurafenib—Hypersensitivity—Gabapentin—epilepsy syndrome	3.29e-05	0.000418	CcSEcCtD
Vemurafenib—Decreased appetite—Topiramate—epilepsy syndrome	3.27e-05	0.000415	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	3.24e-05	0.000412	CcSEcCtD
Vemurafenib—Fatigue—Topiramate—epilepsy syndrome	3.24e-05	0.000412	CcSEcCtD
Vemurafenib—Dizziness—Pregabalin—epilepsy syndrome	3.22e-05	0.000409	CcSEcCtD
Vemurafenib—Constipation—Topiramate—epilepsy syndrome	3.21e-05	0.000408	CcSEcCtD
Vemurafenib—Asthenia—Gabapentin—epilepsy syndrome	3.2e-05	0.000407	CcSEcCtD
Vemurafenib—Nausea—Valproic Acid—epilepsy syndrome	3.2e-05	0.000407	CcSEcCtD
Vemurafenib—Pruritus—Gabapentin—epilepsy syndrome	3.16e-05	0.000402	CcSEcCtD
Vemurafenib—Vomiting—Pregabalin—epilepsy syndrome	3.1e-05	0.000394	CcSEcCtD
Vemurafenib—Rash—Pregabalin—epilepsy syndrome	3.07e-05	0.00039	CcSEcCtD
Vemurafenib—Dermatitis—Pregabalin—epilepsy syndrome	3.07e-05	0.00039	CcSEcCtD
Vemurafenib—Diarrhoea—Gabapentin—epilepsy syndrome	3.06e-05	0.000388	CcSEcCtD
Vemurafenib—Headache—Pregabalin—epilepsy syndrome	3.05e-05	0.000388	CcSEcCtD
Vemurafenib—Body temperature increased—Topiramate—epilepsy syndrome	2.97e-05	0.000378	CcSEcCtD
Vemurafenib—Dizziness—Gabapentin—epilepsy syndrome	2.95e-05	0.000375	CcSEcCtD
Vemurafenib—Nausea—Pregabalin—epilepsy syndrome	2.89e-05	0.000368	CcSEcCtD
Vemurafenib—Vomiting—Gabapentin—epilepsy syndrome	2.84e-05	0.000361	CcSEcCtD
Vemurafenib—Rash—Gabapentin—epilepsy syndrome	2.82e-05	0.000358	CcSEcCtD
Vemurafenib—Dermatitis—Gabapentin—epilepsy syndrome	2.81e-05	0.000358	CcSEcCtD
Vemurafenib—Headache—Gabapentin—epilepsy syndrome	2.8e-05	0.000356	CcSEcCtD
Vemurafenib—Hypersensitivity—Topiramate—epilepsy syndrome	2.77e-05	0.000352	CcSEcCtD
Vemurafenib—Asthenia—Topiramate—epilepsy syndrome	2.7e-05	0.000343	CcSEcCtD
Vemurafenib—Pruritus—Topiramate—epilepsy syndrome	2.66e-05	0.000338	CcSEcCtD
Vemurafenib—Nausea—Gabapentin—epilepsy syndrome	2.65e-05	0.000337	CcSEcCtD
Vemurafenib—Diarrhoea—Topiramate—epilepsy syndrome	2.57e-05	0.000327	CcSEcCtD
Vemurafenib—Dizziness—Topiramate—epilepsy syndrome	2.48e-05	0.000316	CcSEcCtD
Vemurafenib—Vomiting—Topiramate—epilepsy syndrome	2.39e-05	0.000304	CcSEcCtD
Vemurafenib—Rash—Topiramate—epilepsy syndrome	2.37e-05	0.000301	CcSEcCtD
Vemurafenib—Dermatitis—Topiramate—epilepsy syndrome	2.37e-05	0.000301	CcSEcCtD
Vemurafenib—Headache—Topiramate—epilepsy syndrome	2.35e-05	0.000299	CcSEcCtD
Vemurafenib—Nausea—Topiramate—epilepsy syndrome	2.23e-05	0.000284	CcSEcCtD
Vemurafenib—RAF1—Disease—CCR5—epilepsy syndrome	2.8e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PLCB1—epilepsy syndrome	2.8e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—FGF2—epilepsy syndrome	2.8e-06	4.29e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	2.78e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	2.78e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	2.78e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	2.78e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PFKL—epilepsy syndrome	2.78e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCR5—epilepsy syndrome	2.78e-06	4.26e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HTR2A—epilepsy syndrome	2.77e-06	4.25e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HMOX1—epilepsy syndrome	2.76e-06	4.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR7—epilepsy syndrome	2.74e-06	4.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NT5E—epilepsy syndrome	2.73e-06	4.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALAD—epilepsy syndrome	2.73e-06	4.19e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAT—epilepsy syndrome	2.72e-06	4.17e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PRKCB—epilepsy syndrome	2.67e-06	4.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HBEGF—epilepsy syndrome	2.66e-06	4.08e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TXNRD1—epilepsy syndrome	2.66e-06	4.07e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ABCB1—epilepsy syndrome	2.65e-06	4.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—epilepsy syndrome	2.64e-06	4.05e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TSC2—epilepsy syndrome	2.64e-06	4.04e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGT—epilepsy syndrome	2.63e-06	4.04e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.63e-06	4.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SRC—epilepsy syndrome	2.63e-06	4.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT3—epilepsy syndrome	2.61e-06	4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	2.61e-06	4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	2.61e-06	4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TSC2—epilepsy syndrome	2.6e-06	3.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PRKCB—epilepsy syndrome	2.6e-06	3.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—POMC—epilepsy syndrome	2.59e-06	3.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6ST—epilepsy syndrome	2.59e-06	3.97e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TSC2—epilepsy syndrome	2.58e-06	3.96e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AQP1—epilepsy syndrome	2.58e-06	3.96e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—epilepsy syndrome	2.58e-06	3.95e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.58e-06	3.95e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	2.55e-06	3.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADAM10—epilepsy syndrome	2.55e-06	3.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—epilepsy syndrome	2.55e-06	3.91e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MTOR—epilepsy syndrome	2.55e-06	3.9e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NEU1—epilepsy syndrome	2.55e-06	3.9e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UPB1—epilepsy syndrome	2.55e-06	3.9e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ATIC—epilepsy syndrome	2.55e-06	3.9e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—epilepsy syndrome	2.54e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KDR—epilepsy syndrome	2.53e-06	3.87e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—epilepsy syndrome	2.53e-06	3.87e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—epilepsy syndrome	2.52e-06	3.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SRC—epilepsy syndrome	2.52e-06	3.87e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ADSL—epilepsy syndrome	2.5e-06	3.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—epilepsy syndrome	2.48e-06	3.8e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—epilepsy syndrome	2.46e-06	3.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GLUL—epilepsy syndrome	2.45e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	2.45e-06	3.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PRKCB—epilepsy syndrome	2.43e-06	3.73e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HMOX1—epilepsy syndrome	2.43e-06	3.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6ST—epilepsy syndrome	2.42e-06	3.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—S100B—epilepsy syndrome	2.41e-06	3.7e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	2.41e-06	3.69e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAT—epilepsy syndrome	2.4e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6ST—epilepsy syndrome	2.39e-06	3.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SOCS3—epilepsy syndrome	2.39e-06	3.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDC42—epilepsy syndrome	2.38e-06	3.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FOS—epilepsy syndrome	2.37e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—epilepsy syndrome	2.37e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6ST—epilepsy syndrome	2.37e-06	3.64e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	2.37e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GBE1—epilepsy syndrome	2.37e-06	3.63e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—epilepsy syndrome	2.35e-06	3.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—KCNJ11—epilepsy syndrome	2.33e-06	3.58e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CHRM3—epilepsy syndrome	2.33e-06	3.58e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ABCB1—epilepsy syndrome	2.33e-06	3.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CASP8—epilepsy syndrome	2.32e-06	3.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AVP—epilepsy syndrome	2.31e-06	3.54e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCG2—epilepsy syndrome	2.3e-06	3.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	2.25e-06	3.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2C19—epilepsy syndrome	2.25e-06	3.44e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP11A1—epilepsy syndrome	2.23e-06	3.42e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	2.23e-06	3.41e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—POMC—epilepsy syndrome	2.22e-06	3.4e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.22e-06	3.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AQP1—epilepsy syndrome	2.19e-06	3.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HES1—epilepsy syndrome	2.18e-06	3.34e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—epilepsy syndrome	2.17e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—epilepsy syndrome	2.17e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	2.17e-06	3.32e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AGT—epilepsy syndrome	2.16e-06	3.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FYN—epilepsy syndrome	2.12e-06	3.25e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—epilepsy syndrome	2.12e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—H2AFX—epilepsy syndrome	2.11e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NT5E—epilepsy syndrome	2.11e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALAD—epilepsy syndrome	2.11e-06	3.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MEF2C—epilepsy syndrome	2.11e-06	3.23e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.1e-06	3.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—FGF2—epilepsy syndrome	2.1e-06	3.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SRC—epilepsy syndrome	2.04e-06	3.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—YWHAZ—epilepsy syndrome	2.04e-06	3.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NGF—epilepsy syndrome	2.02e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2D6—epilepsy syndrome	2.01e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	2.01e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	2.01e-06	3.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—BCL2—epilepsy syndrome	1.99e-06	3.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	1.98e-06	3.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	1.98e-06	3.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.97e-06	3.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—epilepsy syndrome	1.96e-06	3.01e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—FGF2—epilepsy syndrome	1.96e-06	3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RELA—epilepsy syndrome	1.95e-06	2.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—FGF2—epilepsy syndrome	1.94e-06	2.97e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.93e-06	2.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR2A—epilepsy syndrome	1.92e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—FGF2—epilepsy syndrome	1.92e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ADRA2A—epilepsy syndrome	1.92e-06	2.94e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BCHE—epilepsy syndrome	1.91e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MTOR—epilepsy syndrome	1.91e-06	2.93e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.9e-06	2.92e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AGT—epilepsy syndrome	1.9e-06	2.91e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.89e-06	2.9e-05	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.89e-06	2.9e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—epilepsy syndrome	1.86e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.86e-06	2.85e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.85e-06	2.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—AKT1—epilepsy syndrome	1.85e-06	2.83e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.84e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.84e-06	2.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TSC2—epilepsy syndrome	1.82e-06	2.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC2A1—epilepsy syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGT—epilepsy syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RELA—epilepsy syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—POMC—epilepsy syndrome	1.82e-06	2.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—AKT1—epilepsy syndrome	1.81e-06	2.78e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.8e-06	2.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PLCB1—epilepsy syndrome	1.8e-06	2.76e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TH—epilepsy syndrome	1.79e-06	2.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—epilepsy syndrome	1.78e-06	2.74e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MTOR—epilepsy syndrome	1.78e-06	2.73e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.77e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MTOR—epilepsy syndrome	1.76e-06	2.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—epilepsy syndrome	1.76e-06	2.7e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—epilepsy syndrome	1.75e-06	2.68e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MTOR—epilepsy syndrome	1.75e-06	2.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—epilepsy syndrome	1.75e-06	2.68e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.74e-06	2.66e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—epilepsy syndrome	1.73e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JUN—epilepsy syndrome	1.7e-06	2.61e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.69e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PRKCB—epilepsy syndrome	1.68e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6ST—epilepsy syndrome	1.68e-06	2.57e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—epilepsy syndrome	1.66e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—epilepsy syndrome	1.64e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—epilepsy syndrome	1.63e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	1.61e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—epilepsy syndrome	1.6e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—epilepsy syndrome	1.59e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.58e-06	2.43e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.58e-06	2.42e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	1.57e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—epilepsy syndrome	1.57e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—epilepsy syndrome	1.57e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	1.56e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—epilepsy syndrome	1.55e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.55e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—epilepsy syndrome	1.53e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—epilepsy syndrome	1.53e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—epilepsy syndrome	1.53e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.53e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.53e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.5e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—epilepsy syndrome	1.5e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—epilepsy syndrome	1.5e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.49e-06	2.28e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TH—epilepsy syndrome	1.48e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—epilepsy syndrome	1.48e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—epilepsy syndrome	1.46e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—epilepsy syndrome	1.45e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—epilepsy syndrome	1.44e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—epilepsy syndrome	1.43e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.41e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—epilepsy syndrome	1.41e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	1.41e-06	2.16e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—epilepsy syndrome	1.4e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—epilepsy syndrome	1.39e-06	2.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—epilepsy syndrome	1.36e-06	2.08e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	1.34e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—epilepsy syndrome	1.34e-06	2.05e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—epilepsy syndrome	1.34e-06	2.05e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	1.28e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	1.27e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—epilepsy syndrome	1.27e-06	1.94e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	1.26e-06	1.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RELA—epilepsy syndrome	1.26e-06	1.93e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TH—epilepsy syndrome	1.26e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	1.24e-06	1.91e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.24e-06	1.9e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.24e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MTOR—epilepsy syndrome	1.23e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.22e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.21e-06	1.86e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.2e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.19e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—epilepsy syndrome	1.17e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—epilepsy syndrome	1.15e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—epilepsy syndrome	1.13e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.1e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—epilepsy syndrome	1.1e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.09e-06	1.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—epilepsy syndrome	1.07e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.05e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—epilepsy syndrome	1.04e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.03e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.03e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.03e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.01e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—epilepsy syndrome	9.89e-07	1.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—epilepsy syndrome	9.87e-07	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	9.83e-07	1.51e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—epilepsy syndrome	9.76e-07	1.5e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	9.72e-07	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TH—epilepsy syndrome	9.69e-07	1.49e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—epilepsy syndrome	9.68e-07	1.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—epilepsy syndrome	9.63e-07	1.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—epilepsy syndrome	9.5e-07	1.46e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—epilepsy syndrome	9.48e-07	1.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—epilepsy syndrome	9.35e-07	1.43e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—epilepsy syndrome	8.88e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—epilepsy syndrome	8.77e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—epilepsy syndrome	8.7e-07	1.33e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—epilepsy syndrome	8.2e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—epilepsy syndrome	8.15e-07	1.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	8.09e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—epilepsy syndrome	8.03e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—epilepsy syndrome	7.98e-07	1.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—epilepsy syndrome	7.87e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	7.76e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—epilepsy syndrome	7.43e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—epilepsy syndrome	7.28e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	7.22e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—epilepsy syndrome	6.9e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	6.5e-07	9.96e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—epilepsy syndrome	6.41e-07	9.83e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—epilepsy syndrome	6.33e-07	9.7e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—epilepsy syndrome	6.29e-07	9.65e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—epilepsy syndrome	6.2e-07	9.5e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—epilepsy syndrome	6.14e-07	9.42e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	5.5e-07	8.44e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—epilepsy syndrome	5.33e-07	8.17e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—epilepsy syndrome	4.86e-07	7.44e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	4.25e-07	6.51e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—epilepsy syndrome	3.96e-07	6.06e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.27e-07	5.01e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—epilepsy syndrome	2.77e-07	4.24e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	2.14e-07	3.27e-06	CbGpPWpGaD
